Last updated: 11/07/2018 18:26:40
Risk-adapted management of postoperative nausea and postoperative vomiting: a phase III-study to assess safety and efficacy of intravenous ondansetron and oral disintegrating tablets of ondansetron.
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: Risk-adapted management of postoperative nausea and postoperative vomiting: a phase III-study to assess safety and efficacy of intravenous ondansetron and oral disintegrating tablets of ondansetron.
Trial description: Risk-adapted management of postoperative nausea and postoperative vomiting: a phase III-study to assess safety and efficacy of intravenous ondansetron and oral disintegrating tablets of ondansetron.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Röwer et al., Risikoadaptiertes Management von Übelkeit und Erbrechen mit Ondansetron Anästhesiologie & Intensivmedizin 2001, 42: 409-477
Röwer, “German title: Risikoadaptiertes Management von Übelkeit und Erbrechen mit Ondansetron. (English translation: “Risk adapted management of nausea and vomiting with ondansetron” Oral presentation, German Congress of Anaesthesiology, 13.06.2001;
Medical condition
Nausea and Vomiting, Postoperative
Product
ondansetron
Collaborators
Not applicable
Study date(s)
June 2000 to November 2000
Type
Not applicable
Phase
3
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2000-17-11
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website